MariTide: Amgen's Monthly Weight Loss Injection That Could Replace Weekly GLP-1 Shots

MariTide (maridebart cafraglutide, formerly known as AMG 133) is an investigational antibody-peptide conjugate developed by Amgen for the treatment of obesity. It represents a fundamentally different approach to weight loss pharmacotherapy — not just a new drug in an existing class, but an entirely new drug class.

The molecule is bi-functional: one component activates GLP-1 receptors (the same target as semaglutide and liraglutide), promoting satiety and improving insulin sensitivity. The other component blocks GIP (glucose-dependent insulinotropic polypeptide) receptors. This is scientifically notable because tirzepatide (Zepbound/Mounjaro) — currently the most effective approved weight loss drug — activates GIP receptors rather than blocking them. The question of whether GIP agonism or antagonism produces better metabolic outcomes is one of the most active debates in obesity pharmacology.

The game-changing feature is the dosing schedule. The antibody component gives MariTide a half-life of approximately 21 days — dramatically longer than any peptide-based GLP-1 drug. This enables once-monthly subcutaneous injection, compared to the weekly injections required by Ozempic, Wegovy, Zepbound, and Mounjaro. For patients who find weekly injections burdensome, forget doses, or struggle with adherence, monthly dosing could substantially improve real-world outcomes.

Phase 2 results were published in the New England Journal of Medicine, and the drug is now in Phase 3 trials.

The Phase 2 data, published in the New England Journal of Medicine, established MariTide as a serious contender in the weight loss drug landscape.

Weight loss in participants without diabetes. At 52 weeks, participants receiving MariTide lost approximately 20% of their body weight, compared to 2.6% in the placebo group. This is comparable to the highest doses of tirzepatide (which produces 20–22% weight loss at 72 weeks) and superior to semaglutide 2.4 mg (approximately 15% at 68 weeks).

Weight loss in participants with type 2 diabetes. Participants with obesity and type 2 diabetes lost approximately 17% of body weight, compared to 1.4% with placebo. MariTide also produced a sustained HbA1c reduction of up to 2.2 percentage points — clinically meaningful glycemic improvement.

Weight loss had not plateaued. Perhaps the most significant finding was that weight loss was still trending downward at 52 weeks, suggesting that longer treatment durations could produce additional weight reduction. Most GLP-1 drug trials show weight loss plateauing between 60–72 weeks. If MariTide’s weight loss curve continues to decline, it could ultimately surpass existing drugs in total efficacy.

Cardiometabolic improvements. Beyond weight and HbA1c, MariTide improved waist circumference, blood pressure, high-sensitivity C-reactive protein (an inflammation marker), and select lipid parameters. The breadth of metabolic improvement suggests multi-system benefits similar to those observed with GLP-1 agonists.

MariTide’s dual mechanism raises important questions about the role of GIP in obesity treatment — because the two most promising weight loss drugs of this generation take opposite approaches to GIP.

Tirzepatide (Zepbound) activates GIP receptors. The logic: GIP is an incretin hormone that enhances insulin secretion and may have direct effects on fat tissue and appetite centers. Activating both GLP-1 and GIP receptors produces greater weight loss than GLP-1 activation alone.

MariTide blocks GIP receptors. The logic: GIP signaling in certain contexts promotes fat storage and may counteract some weight loss effects. Blocking GIP while activating GLP-1 could redirect metabolic signaling away from fat deposition.

Both approaches produce ~20% weight loss. This is the paradox that has puzzled researchers. The answer likely involves the complexity of GIP receptor biology — GIP has different effects in different tissues (pancreas, fat, brain), and its role may shift depending on metabolic context. Whether GIP agonism or antagonism produces better long-term outcomes will only be resolved by Phase 3 head-to-head data.

The antibody-peptide conjugate platform. MariTide’s long half-life comes from its antibody backbone, which is slowly cleared by the body. The peptide components (GLP-1 agonist and GIP antagonist) are linked to this antibody, effectively creating a slow-release system that maintains therapeutic drug levels for weeks after a single injection. This is an engineering innovation — standard GLP-1 peptides are cleared within days, which is why they require weekly dosing.

One of the most clinically relevant findings from the Phase 2 trial was MariTide’s GI tolerability profile, which may represent a meaningful improvement over weekly GLP-1 drugs.

GI events concentrated at first dose. The most frequently reported adverse events were gastrointestinal — nausea, vomiting, and diarrhea — consistent with GLP-1 class effects. However, these events were predominantly limited to the initial dose and became substantially less frequent with subsequent monthly injections when dose escalation was used.

Dose escalation preserved efficacy. Importantly, using a gradual dose-escalation approach did not compromise weight loss efficacy while significantly reducing GI adverse events. This is a meaningful finding because with weekly GLP-1 drugs, GI symptoms often recur with each dose increase during the multi-month titration period.

Comparison to weekly injectables. With semaglutide and tirzepatide, patients typically experience GI symptoms during each of 4–5 dose-escalation steps over 16–20 weeks. MariTide’s monthly dosing with front-loaded GI events could mean a shorter and less burdensome adjustment period. Phase 3 data will be needed to confirm whether this tolerability advantage holds in larger, more diverse populations.

Discontinuation rates. Detailed discontinuation data from Phase 2 suggest that MariTide’s tolerability is comparable to or better than existing GLP-1 drugs, though Phase 3 trials will provide more definitive numbers.

MariTide is currently in Phase 3 clinical development, with multiple large-scale trials underway. Here is the expected timeline.

Phase 3 trials (current). Amgen has initiated several Phase 3 studies evaluating MariTide across different patient populations — obesity with and without diabetes, and potentially cardiovascular outcomes. Trial sizes are expected to be in the thousands of participants, as required for FDA approval in obesity.

Results expected 2026–2027. Phase 3 readouts are anticipated beginning in late 2026, with the full program completing through 2027. The trials are designed to confirm Phase 2 efficacy, establish long-term safety, and potentially demonstrate cardiovascular benefits.

FDA filing and approval. If Phase 3 results are positive, Amgen would file a Biologics License Application (BLA) with the FDA, likely in 2027. Standard FDA review takes 10–12 months, with potential for priority review given the public health significance of the obesity indication. Approval could come as early as late 2027 or 2028.

The competitive landscape. By the time MariTide reaches market, it will compete against established weekly injectables (Wegovy, Zepbound), oral options (Foundayo, oral Wegovy), and potentially other long-acting formulations. MariTide’s monthly dosing would be its primary differentiator — particularly for patients who find weekly injections burdensome or have adherence challenges.

MariTide represents a genuinely new approach to obesity pharmacotherapy — not just a better GLP-1 drug, but a different drug class with a different mechanism and a potentially transformative dosing schedule. The Phase 2 data showing ~20% weight loss with monthly dosing and favorable GI tolerability positions it as a serious contender to disrupt the weekly injection paradigm.

The key questions that Phase 3 must answer: Does the GIP antagonism approach hold up in larger populations? Does the non-plateaued weight loss curve translate to even greater efficacy at longer timepoints? Are there unique safety signals that emerge with antibody-peptide conjugate biology? And can monthly dosing genuinely improve real-world adherence and outcomes versus weekly alternatives?

For patients currently on or considering GLP-1 therapy, MariTide is not yet available and should not delay current treatment. For the field as a whole, MariTide’s Phase 3 results will be among the most closely watched data readouts in obesity medicine over the next 18 months.